Match each of the following complex ambulatory patient profiles with the single most appropriate, evidence-based preventive screening or immunization recommendation.
- A 61-year-old woman with chronic congestive heart failure and diabetes mellitus. She received a 20-valent pneumococcal conjugate vaccine (PCV20) at age 60.Administration of a single dose of respiratory syncytial virus (RSV) vaccine
- A 24-year-old woman who is newly diagnosed with HIV (CD4 count 550 cells/mm³). Her last cervical cytology test was normal at age 21.Cervical cytology testing now and repeated annually for three consecutive years
- A 35-year-old man with recently diagnosed severe rheumatoid arthritis. He had chickenpox in childhood and is scheduled to begin immunosuppressive therapy with rituximab next month.Administration of the recombinant zoster vaccine (RZV) series
- A 72-year-old man with end-stage, oxygen-dependent COPD who is bedbound. He has a 50 pack-year smoking history and quit 2 years ago.Discontinuation of annual low-dose computed tomography (LDCT) lung cancer screening
Cevap
The 61-year-old with heart failure receives the RSV vaccine; the newly diagnosed 24-year-old with HIV undergoes annual cervical cytology; the 35-year-old starting immunosuppression receives the RZV series; and the 72-year-old with end-stage COPD discontinues LDCT screening.
Each patient requires a highly specific deviation from average-risk screening and immunization pathways. The RSV vaccine targets adults 60-74 with high-risk cardiopulmonary conditions. HIV infection mandates an accelerated annual cervical cytology schedule. Targeted immunosuppressive therapy expands the RZV indication to young adults over 19. Finally, end-stage, bedbound conditions necessitate the cessation of cancer screening because the patient is no longer a candidate for curative intent.
Adım Adım Çözüm
Anahtar Kavram
Application of advanced preventive care guidelines, emphasizing nuanced modifications required for specific comorbidities, immunocompromised states, and end-stage life-limiting conditions.
Tahmini Süre:2m 30s